The effect of SOVODAK in the treatment of COVID-19 patients

Phase 3

Recruiting

• Conditions: COVID-19.; B34.2; Coronavirus infection, unspecified

• Registration Number: IRCT20200403046926N1
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Diagnosis by CT scan with clinical symptoms
Consent to attend the study
Lymphocyte count less than 1100
Positive CRP test

Exclusion Criteria

History of kidney failure
Pregnancy
Amiodarone consumer

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptoms ending. Timepoint: During the study. Method of measurement: Clinical examination.;Lymphopenic Status. Timepoint: Before the intervention and the seventh day. Method of measurement: Counting lymphocytes.;C-reactive protein Status. Timepoint: Before the intervention and the seventh day. Method of measurement: C-reactive protein serological test.;Saturation of Peripheral Oxygen. Timepoint: Before the intervention and the seventh day. Method of measurement: Pulseimetry.

Secondary Outcome Measures

Name	Time	Method
eed hospitalization. Timepoint: Depending on the situation. Method of measurement: Depending on the patient's condition.